射频消融与索拉菲尼治疗原发性肝癌的疗效观察

目的评价肝癌射频消融治疗与索拉菲尼对肝癌患者的疗效。方法回顾性收集26例肝癌患者的临床资料，其中有12名患者行射频消融治疗后因经济等其他原因未服用索拉菲尼，8名患者在发现有原发性肝癌后同时行射频治和口服索拉菲尼治疗，比较单行射频消融术与射频消融术联合索拉菲尼两组患者平均射频间隔时间。另有6名患者在服用索拉菲尼前有过射频消融治疗，以开始服用索拉菲尼为界，比较服用前和服用后射频治疗的平均间隔时间。结果射频消融后同时服用索拉菲尼组患者行射频消融的平均间隔时间（5．23±1．21）月／次长于射频消融后未服用索拉菲尼组（3．90±1．321）月／次，差异有统计学意义（t=3．28，P=0．013）；服用索拉菲尼后行射频消融治疗的平均射频间隔时间，长于服用索拉菲尼前的间隔时间。（t=3．247，P=0．023）。结论对于接受射频消融治疗的肝癌患者，联合服用索拉菲尼后可以有效抑制肿瘤的生长，延长射频消融治疗的间隔。

Clinical study of radiofrequency ablation therapy and sorafenib for hepatocellular carcinoma

Objective To evaluate the radiofrequency ablation and sorafenib in patients with liver cancer and prognosis. Methods Retrospectively, to collecting 26 cases of hepatocellular carcinoma patients with clinical data. There were 12 patients underwent radiofrequeney treatment not taking sorafenib in the second group, due to economic and other reasons. There were 8 patients with primary liver cancer found after radiofrequency treatment while taking sorafenib. To comparing the average RF interval between two groups, In addition, there were other 6 patients underwent radiofrequeney treatment before taking sorafenib. By starting taking sorafenib for the sector, we compared the frequency before and after radiofre- quency ablation. Results The average interval frequency of the first group （ 5.23 ±1.21 ） was higher than the second group（3.90 ±1. 321 ）. Difference was statistically significant. Taking sorafenib underwent radiofrequency ablation fre- quency is greater than the average interval before taking sorafenib average interval frequency （ t = 3. 247, P = 0. 023 ）. Conclusion For the hepatocellular carcinoma patients received radiofrequency ablation,the joint after taking sorafenib can inhibit tumor growth and prolong RF interval.